EFFICACY AND SAFETY OF TOFACITINIB RETREATMENT FOR ULCERATIVE COLITIS AFTER TREATMENT INTERRUPTION: AN UPDATE OF RESULTS FROM THE OCTAVE CLINICAL TRIALS

Julian Panés  ¹     Jean-Frédéric Colombel  ²     Severine Vermeire  ³     Marla C. Dubinsky  ³     Ala Sharara  ⁴     Nervin Lawendy  ⁵     Wenjin Wang  ⁵     Leonardo Salese  ⁵     Chinyu Su  ⁵     Irene Modesto  ⁶     Xiang Guo  ⁶     Edward V. Loftus Jr.  ^7    
1 Hospital Clínic de Barcelona, IDIBAPS, CIBERehd, Barcelona, Spain
² Icahn School of Medicine at Mount Sinai, New York, United States
³ University Hospitals Leuven, Leuven, Belgium
⁴ American University of Beirut Medical Center, Beirut, Lebanon
⁵ Pfizer Inc, Collegeville, PA, United States
⁶ Pfizer Inc, New York, United States
⁷ Mayo Clinic, Rochester, United States

Session
IBD (Posters)

Conference
UEG Week Virtual 2020

Citation
United European Gastroenterology Journal 2020; 8 (Supplement 1)